A focused tracking guide for oral NADH supplementation in fatigue, cognition, and Parkinson disease contexts.
At a glance
NADH is the reduced form of NAD+, the electron-carrying coenzyme. While NAD+ accepts electrons, NADH delivers them to the electron transport chain to drive ATP production. Oral NADH has been studied in narrower contexts than NAD+ precursors: chronic fatigue syndrome, mild cognitive complaints, jet lag, and supportive use in Parkinson's disease.
Oral NADH is absorbed in small amounts and may contribute to cellular NAD+ pools, though the pharmacokinetics are not as clean as marketing suggests. Most evidence is from small trials. The signals that have appeared most consistently are modest improvements in subjective fatigue and some cognitive measures in specific populations.
Typical use looks like:
For most users, no specific labs are needed. If you are pursuing NADH for chronic fatigue, a broader fatigue workup with a clinician is appropriate first: thyroid, iron, B12, ferritin, vitamin D, and sleep evaluation.
The signal for NADH is modest and population-specific. People with documented fatigue conditions are more likely to notice change than healthy adults seeking an extra edge. Set a clear baseline; the improvements are often slow enough that recall bias dominates.
In Peptide IA, log dose and timing each morning and energy and cognitive scores in the evening. A four-week trial with weekly averages is enough to see whether your baseline has shifted.
Oral NADH is one of the better-tolerated entries in the NAD-family supplement category, with modest evidence and a low-risk profile. Trial it deliberately, measure honestly, and stop if nothing changes.
Peptide IA is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.